Vaccination of carp against SVCV with an oral DNA vaccine or an insect cells-based subunit vaccine

C.W.E. Embregts, D. Rigaudeau, L. Tacchi, G.P. Pijlman, L. Kampers, T. Veselý, D. Pokorová, P. Boudinot, G.F. Wiegertjes, M. Forlenza*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

33 Citations (Scopus)


We recently reported on a successful vaccine for carp against SVCV based on the intramuscular injection of a DNA plasmid encoding the SVCV glycoprotein (SVCV-G). This shows that the intramuscular (i.m.) route of vaccination is suitable to trigger protective responses against SVCV, and that the SVCV G-protein is a suitable vaccine antigen. Yet, despite the general success of DNA vaccines, especially against fish rhabdoviruses, their practical implementation still faces legislative as well as consumer's acceptance concerns. Furthermore, the i.m. route of plasmid administration is not easily combined with most of the current vaccination regimes largely based on intraperitoneal or immersion vaccination. For this reason, in the current study we evaluated possible alternatives to a DNA-based i.m. injectable vaccine using the SVCV-G protein as the vaccine antigen. To this end, we tested two parallel approaches: the first based on the optimization of an alginate encapsulation method for oral delivery of DNA and protein antigens; the second based on the baculovirus recombinant expression of transmembrane SVCV-G protein in insect cells, administered as whole-cell subunit vaccine through the oral and injection route. In addition, in the case of the oral DNA vaccine, we also investigated the potential benefits of the mucosal adjuvants Escherichia coli lymphotoxin subunit B (LTB). Despite the use of various vaccine types, doses, regimes, and administration routes, no protection was observed, contrary to the full protection obtained with our reference i.m. DNA vaccine. The limited protection observed under the various conditions used in this study, the nature of the host, of the pathogen, the type of vaccine and encapsulation method, will therefore be discussed in details to provide an outlook for future vaccination strategies against SVCV.
Original languageEnglish
Pages (from-to)66-77
JournalFish and Shellfish Immunology
Early online date19 Mar 2018
Publication statusPublished - Feb 2019


  • Alginate encapsulation
  • Baculovirus
  • DNA vaccine
  • Insect cells
  • SVCV glycoprotein


Dive into the research topics of 'Vaccination of carp against SVCV with an oral DNA vaccine or an insect cells-based subunit vaccine'. Together they form a unique fingerprint.

Cite this